Coadministration of lapatinib with moderate inhibitors of CYP3A4 should proceed with caution and clinical adverse reactions should be carefully monitored.
4 inhibiitoritega on vajalik ettevaatus ning patsienti tuleb hoolikalt jälgida kliiniliste kõrvaltoimete suhtes.